Black women are drastically underrepresented in clinical trials. Only 3% of clinical trial participants leading to FDA approval of cancer drugs between 2008 and 2018 were Black. The consequences are dire—too many Black women are missing out on access to newly emerging and often life-extending treatments.
Join our friends from Touch BBCA as they discuss their new educational campaign, When WE Tri(al), and share how participation in clinical trials will change the game on advancing science for all black women diagnosed with breast cancer.
